Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
This study is an open-label study where all subjects will receive active drug, reslizumab.
Subjects are able to enter this trial only through completion of study Res-05-0002
(NCT00538434).
The goal of the study is to show longer term safety and efficacy in pediatric subjects who
have eosinophilic esophagitis.